Breast Cancer | Endocrine Treatment of Metastatic Breast Cancer: New Advances; Patient Education Implications

A presentation from Dr O’Shaughnessy featuring emerging research and cases from her practice. Introduction (00:00) Program overview: Dr Love Estrogen and Progesterone Receptors; Clinical Use of Endocrine Treatment (1:20) Case: A woman in her early 60s with ER/PR-positive, HER2-negative breast cancer (BC) who experienced intolerable arthralgias with adjuvant aromatase inhibition and was switched to tamoxifen (7:08) First-Line Endocrine Therapy for Metastatic Disease: Role of CDK4/6 Inhibitors (12:44) Case: A woman in her mid-60s with ER/PR-positive de novo metastatic BC (mBC) who received palbociclib/letrozole (12:54) Case: A woman in her mid-50s with ER/PR-positive, HER2-negative BC who developed metastatic disease after receiving 4 years of adjuvant letrozole and started treatment with ribociclib/fulvestrant (27:39) Case: A woman in her early 60s who received abemaciclib/exemestane for ER/PR-positive, HER2-negative mBC to the brain and bone (33:09) Second-Line Endocrine Therapy for Metastatic Disease: Role of mTOR Inhibitors (42:18) Case: A woman in her late 60s with ER/PR-positive, HER2-negative mBC who received exemestane/everolimus after disease progression on a CDK4/6 inhibitor (42:26) New Approaches Under Investigation (51:47) Assessing and Optimizing Treatment Adherence (59:00) Case: A woman in her early 30s with ER/PR-positive, HER2-negative BC who demonstrated poor adherence to adjuvant endocrine therapy because of weight gain (59:09) Select publications